Australia Head And Neck Cancer Therapeutics Market Size & Outlook
Related Markets
Australia head and neck cancer therapeutics market highlights
- The Australia head and neck cancer therapeutics market generated a revenue of USD 22.3 million in 2024 and is expected to reach USD 68.5 million by 2033.
- The Australia market is expected to grow at a CAGR of 13.3% from 2025 to 2033.
- In terms of segment, immunotherapy was the largest revenue generating type in 2024.
- Immunotherapy is the most lucrative type segment registering the fastest growth during the forecast period.
Head and neck cancer therapeutics market data book summary
| Market revenue in 2024 | USD 22.3 million |
| Market revenue in 2033 | USD 68.5 million |
| Growth rate | 13.3% (CAGR from 2025 to 2033) |
| Largest segment | Immunotherapy |
| Fastest growing segment | Immunotherapy |
| Historical data | 2021 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Chemotherapy, Immunotherapy, Targeted Therapy |
| Key market players worldwide | Eli Lilly and Co, Sanofi SA, Merck & Co Inc, Bristol-Myers Squibb Co, AstraZeneca PLC, Takeda Pharmaceutical Co Ltd, Teva Pharmaceutical Industries Ltd, Roche Holding AG ADR, Clinigen Group |
Other key industry trends
- In terms of revenue, Australia accounted for 1.0% of the global head and neck cancer therapeutics market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Asia Pacific, Japan head and neck cancer therapeutics market is projected to lead the regional market in terms of revenue in 2033.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 267.9 million by 2033.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Head And Neck Cancer Therapeutics Market Scope
Head And Neck Cancer Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Clinigen Group | View profile | 1001-5000 | Burton-on-trent, St. Helens, United Kingdom, Europe | http://clinigengroup.com |
| Takeda Pharmaceutical Co Ltd | View profile | 49095 | 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan, 103-8668 | https://www.takeda.com |
| AstraZeneca PLC | View profile | 89900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | https://www.astrazeneca.com |
| Eli Lilly and Co | View profile | 43000 | Lilly Corporate Center, Indianapolis, IN, United States, 46285 | https://www.lilly.com |
| Bristol-Myers Squibb Co | View profile | 34100 | Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543 | https://www.bms.com |
| Merck & Co Inc | View profile | 72000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | https://www.merck.com |
| Sanofi SA | View profile | 87994 | 46, avenue de la Grande Armée, Paris, France, 75017 | https://www.sanofi.com |
| Roche Holding AG ADR | View profile | 103605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | https://www.roche.com |
| Teva Pharmaceutical Industries Ltd | View profile | 37851 | 124 Dvora HaNevi’a Street, Tel Aviv, Israel, 6944020 | https://www.tevapharm.com |
Australia head and neck cancer therapeutics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to head and neck cancer therapeutics market will help companies and investors design strategic landscapes.
Immunotherapy was the largest segment with a revenue share of 68.16% in 2024. Horizon Databook has segmented the Australia head and neck cancer therapeutics market based on chemotherapy, immunotherapy, targeted therapy covering the revenue growth of each sub-segment from 2021 to 2033.
Australia’s head and neck cancer therapeutics market is expected to grow significantly due to research collaborations, favorable government initiatives, and increased prevalence of the target disease. According to Healthdirect Australia, every year, there are over 5,100 cases of head and neck cancer in the country.
Furthermore, according to Cancer Australia, in 2022, the estimated mortality rate for head and neck cancer was 3.7 deaths per 100,000 persons. In December 2023, Shanghai Junshi Biosciences Co., Ltd received acceptance from the Therapeutic Goods Administration (TGA) for the New Chemical Entity (NCE) application for toripalimab.
The drug, in combination with cisplatin and gemcitabine, is intended for the treatment of locally advanced nasopharyngeal carcinoma. The approval of anticancer drugs in the country is expected to boost the growth of this market.
Reasons to subscribe to Australia head and neck cancer therapeutics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Australia head and neck cancer therapeutics market databook
-
Our clientele includes a mix of head and neck cancer therapeutics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia head and neck cancer therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into Australia head and neck cancer therapeutics market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Partial client list
Australia head and neck cancer therapeutics market size, by type, 2021-2033 (US$M)
Australia Head And Neck Cancer Therapeutics Market Outlook Share, 2024 & 2033 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
